Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Cancer × Dasatinib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Leukemia, Myeloid, Chronic-Phase 16 Leukemia 9 Breast Neoplasms 9 Prostatic Neoplasms 7 Neoplasm Metastasis 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Recurrence 5 Philadelphia Chromosome 4 Pancreatic Neoplasms 4 Leukemia, Myeloid, Acute 4 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Melanoma 3 Lung Neoplasms 3 Burkitt Lymphoma 3 Blast Crisis 3 Triple Negative Breast Neoplasms 2 Salivary Gland Neoplasms 2 Polycythemia Vera 2 Ovarian Neoplasms 2 Neuroblastoma 2 Multiple Myeloma 2 Lymphoma 2 Leukemia, Myelomonocytic, Chronic 2 Gliosarcoma 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Brain Neoplasms 2

Interventions

relatlimab 2 linrodostat 2 Nivolumab 2 Ipilimumab 2 Vorinostat 1 Trastuzumab 1 IFL protocol 1 Gemcitabine 1 Dasatinib 1 Cetuximab 1 BMS-813160 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02750514 2021-03-22

FRACTION-Lung

Bristol-Myers Squibb

Phase 2 Terminated

295 enrolled 21 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡